If the "trial is proceeding well", I think they have seen some sort of efficacy in patient 6th. Remember at an equivalent dose in animals, all liver cell in the liver has been transduced and the vector copied many times. If they have not seen some sort of efficacy what would be the point to open another trial site and spend more cash. Relax guys, It may take a little longer, but not gene therapy has been approved in USA yet, not even Uniqure. If we are able to be the first to get a Gene therapy approved It will mean a lot. Plus, more trial sites means it will be easy to find patients for Heparma later.
- Forums
- ASX - By Stock
- BLT
- Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL
Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL, page-14
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)